Beacon Pharmaceuticals Limited has recommended a 15 per cent cash dividend to its shareholders for the financial year 2020-21.
The dividend declaration came at a meeting of the listed drug-maker’s board of directors held on Sunday.
The latest dividend was 9 per cent higher than that of the previous year. It disbursed a 6 per cent dividend to its investors in the previous financial year.
The company bagged a healthy profit in FY21 and hereby declared higher dividend for the year.
It reported earnings per share of Tk 3.74 for the year ending on June 30, up by 1.26 per cent from Tk 1.65 of previous year.
The company also reported net asset value per share of Tk 23.18 and net operating cash flow per share of Tk 0.85 for FY21, against Tk 20.04 and Tk 1.26 respectively of the previous year.
To get the recommended dividend approved, the company will hold annual general meeting on December 29 while the record date is set as December 20.
Each of Beacon Pharma shares changed hands at Tk 227.70 at the Dhaka bourse on Sunday.
The company’s market capitalization is around Tk 5,110 crore and paid-up capital is Tk 231 crore. It was listed with capital market in 2010 and carries out share trading under ‘B’ category.
Beacon Pharmaceuticals Limited is an oncology company and one of the leading and fastest growing pharmaceutical companies of Bangladesh. It started operation in 2006.
The company manufactures more than 200 generic drugs. It started exporting medicine in 2012.
Beacon Pharmaceuticals received a Good Manufacturing Practice (GMP) certificate from the Syrian Arab Republic on August. This paved the way for the export of Beacon drugs to Syria.